Market Dynamics

The growth of the global vagus nerve stimulation market is primarily driven by the rising prevalence of neurological disorders, including epilepsy and other chronic conditions, which is increasing the demand for effective treatment options. Healthcare professionals are actively promoting neurostimulation therapies such as VNS to achieve better clinical outcomes. Moreover, rising investments in research and development and collaborations between medical device manufacturers and healthcare institutions are accelerating innovation in neurostimulation technologies.

However, the market faces restraints such as the high cost of VNS devices and procedures, which limit patient accessibility, particularly in low and middle-income regions. Additionally, stringent regulatory requirements for approval and reimbursement pose challenges for market entry and expansion.

On the other hand, expanding VNS applications into emerging indications and novel patient populations presents substantial untapped potential. Increasing clinical trials exploring VNS for conditions such as chronic pain and inflammatory diseases are opening new avenues for market growth. Furthermore, growing awareness among physicians and patients regarding non-pharmacological treatment options is likely to strengthen adoption and support long-term market expansion.

Market Highlights

• Product: The external VNS devices segment is expected to register the fastest CAGR growth of 9.05%.
• Application: The epilepsy segment dominated the market with a revenue share of 58.89% in 2025.
• End User: The hospitals segment dominated the market in 2025, owing to higher patient inflow, advanced surgical infrastructure, and the availability of skilled neurologists.
• Regional Insights: North America dominated the global market, accounting for 54.78% share in 2025, owing to the high prevalence of neurological and psychiatric disorders.